EN DE
Watch Changchun High & New Technology Industries Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Changchun High & New Technology Industries Group Inc (000661) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Changchun High & New Technology Industries Group Inc stock ¥61.70, price ¥74.80, that is 17.5% below the price, quality 45 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE0000007J8

CH Changchun High & New Technology Industries Group Inc logo Thin data Nov 12, 2026

Changchun High & New Technology Industries Group Inc

000661 · SHE

Expensive (fair value 18% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Quality 45/100 
Expensive Growth (revenue 5y +7.1 %/yr in CNY) 
Loss over the last twelve months · -3.2% net margin (TTM) · fiscal year 2025 1.3% 
0.2% dividend yield · Token dividend
Revenue last quarter 18% below a year ago. 
Changed on Oct 27: ¥33.45 → ¥60.16 
Fair value ¥61.70 · Overvalued 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (3/12) 
Narrow moat 30/100 · thin data
Thin data 
Watch Changchun High & New Technology Industries Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥382.21 ¥62.80 Fair Value ¥61.70 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range ¥62.80 – ¥382.21 · fair‑value band ¥59.20 – ¥65.93 · the ¥74.80 price screens above the ¥61.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Changchun High & New Technology Industries Group in your weekly email

Every Wednesday you see whether Changchun High & New Technology Industries Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China.

Show moreShow less

The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal spray live attenuated influenza; xueshuanxinmaining tablet; and yinhuamiyanling tablet.

It also develops real estate properties. The company was founded in 1993 and is based in Changchun, China.

Stock analysis

Changchun High & New Technology Industries Group Inc (000661) currently trades at ¥74.80, while our model-based Fair Value estimate is ¥61.70, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥124.34 per share, and 6 of the 16 models we run sit above the ¥74.80 price.

Bear case: the Growth Earnings group reads lowest at ¥9.26, and 10 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥59.20 (bear) to ¥65.93 (bull), the price of ¥74.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Changchun High & New Technology Industries Group Inc reported revenue of 12.1B CNY in FY2025 versus 10.7B CNY in FY2021, a compound +3.0%/yr. Reported net income was 155M CNY in FY2025, compounding −54.9%/yr from FY2021.

Key figures

Market cap 30.5B CNY (≈ $4.6B) Mid · P/S ratio 2.65 · EPS (TTM) ¥−0.8700 · Dividend yield 0.2% · Net margin −3.2% · Return on equity −2.0% · Return on assets (EBIT) 14.3% (5-year average) · Operating margin 13.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −18%, 000661 screens cheaper than that median.

Fair Value models

Bear ¥59.20 Fair Value ¥61.70 Bull ¥65.93
Price ¥74.80 · Downside -17.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥32.89 ¥34.28 ¥36.63 76
EPV ¥68.46 ¥79.36 ¥88.86 74
ROIC Compounder ¥77.55 ¥111.53 ¥144.15 71
All 16 models by family
Earnings-Based
Graham-Dodd ¥2.58 ¥15.27 ¥21.26 63
Lynch FV ¥5.60 ¥8.00 ¥10.40 61
PEG = 1.0 ¥5.60 ¥8.00 ¥10.40 57
EPV ¥68.46 ¥79.36 ¥88.86 74
Dividend Discount
Gordon GGM ¥24.15 ¥49.73 ¥78.03 66
DDM Multi-Stage ¥24.15 ¥42.17 ¥52.26 67
Multiples
P/E Multiple ¥6.27 ¥8.36 ¥10.45 63
P/S Multiple ¥4.84 ¥6.46 ¥8.07 58
P/B Multiple ¥130.82 ¥174.42 ¥218.03 55
EV/EBIT ¥114.24 ¥148.58 ¥182.92 66
EV/EBITDA ¥115.65 ¥150.45 ¥185.26 67
EV/Revenue ¥73.43 ¥100.09 ¥126.75 54
Asset-Based
NCAV (Graham) ¥9.28 ¥14.06 ¥17.58 54
Economic Profit
Residual Income ¥32.89 ¥34.28 ¥36.63 76
ROIC Compounder ¥77.55 ¥111.53 ¥144.15 71
Growth Earnings
Growth-Adj P/E ¥6.48 ¥9.26 ¥12.04 67

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 28
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 77
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: +17.5% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−44.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.9%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−44.9% vs −12.4%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.39% → 25%
Pace: the 5-year rate starts in 2020 (pandemic)

000661 screens overvalued: fair value 18% below the price. Compare with Merck KGaA →

Compare Changchun High & New Technology Industries Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −17.5% · Below median
Profitability
Return on assets 0.5% · Below median
Net margin (12 months) −3.2% · Bottom 25%
Operating margin (12 months) 13.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) −18.0% · Bottom 25%
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.39× · Cheaper than median
P/S (12 months) 2.77× · Pricier than median
EV/EBITDA 27.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)4 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs 000661
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs 000661
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs 000661
Haleon plc HLN $9.20 $8.47 −8% vs 000661
Merck KGaA MRK €149.70 €108.83 −27% vs 000661
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs 000661
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs 000661
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs 000661
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs 000661
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs 000661

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Changchun High & New Technology Industries Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Changchun High & New Technology Industries Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/000661

Frequently asked questions

Is Changchun High & New Technology Industries Group Inc (000661) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ¥61.70 versus a price of ¥74.80, about 18% lower (overvalued).
What is the fair value of 000661?
Our model-based fair value for Changchun High & New Technology Industries Group Inc is ¥61.70 (as of Nov 12, 2026), built from audited fundamentals. The current price: ¥74.80.
What is the quality score of 000661?
Changchun High & New Technology Industries Group Inc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Changchun High & New Technology Industries Group Inc (000661)?
Our model-based price target is the fair value of ¥61.70 (as of Nov 12, 2026) from 16 valuation models. Cautious scenario ¥59.20, optimistic scenario ¥65.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Changchun High & New Technology Industries Group Inc stock forecast for 2026?
Our models put fair value at ¥61.70, about 18% lower versus a price of ¥74.80 (overvalued). Cautious scenario ¥59.20, optimistic scenario ¥65.93. The calculation is refreshed regularly with new filings.
What is the revenue of Changchun High & New Technology Industries Group Inc (000661)?
Changchun High & New Technology Industries Group Inc reported trailing-twelve-month revenue of about 11.0B CNY (latest available figure, as of Nov 12, 2026).
Does Changchun High & New Technology Industries Group Inc pay a dividend?
Changchun High & New Technology Industries Group Inc currently shows a dividend yield of 0.21% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Changchun High & New Technology Industries Group Inc (000661) and when is the ex-dividend date?
Changchun High & New Technology Industries Group Inc pays a dividend of ¥0.16 per share a year, a dividend yield of 0.2%. The last ex-dividend date was May 25, 2026. A dividend has been paid every year since 2013. The payout ratio is 42.1% of earnings. Our assessment: Token dividend. At a yield of 0.2% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.2% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Changchun High & New Technology Industries Group Inc (000661)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Changchun High & New Technology Industries Group Inc it is ¥61.70 per share (as of Nov 12, 2026), against a price of ¥74.80. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Changchun High & New Technology Industries Group Inc stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 000661 trades above its calculated fair value: price ¥74.80, fair value ¥61.70, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000661?
No. The price is what the market pays today (¥74.80); the fair value is what the company's own numbers justify (¥61.70). For Changchun High & New Technology Industries Group Inc the two are ¥13.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Changchun High & New Technology Industries Group Inc worth?
The market values Changchun High & New Technology Industries Group Inc at about 30.5B CNY (market capitalisation, as of Nov 12, 2026). Per share that is ¥74.80; our models calculate a fair value of ¥61.70 per share.
What do the bullish and bearish scenarios say about 000661?
Our models span a range for Changchun High & New Technology Industries Group Inc: cautious scenario ¥59.20, base ¥61.70, optimistic ¥65.93 per share (as of Nov 12, 2026, price ¥74.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Changchun High & New Technology Industries Group Inc (000661)?
Balance-sheet figures for Changchun High & New Technology Industries Group Inc (as of Nov 12, 2026): return on equity −2.0%, debt of 0.06 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 000661 from its 52-week high?
Changchun High & New Technology Industries Group Inc trades at ¥74.80, about 28% below its 52-week high of ¥103.36 and 19% above the low of ¥62.80 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥61.70 is for.
Which stocks are comparable to Changchun High & New Technology Industries Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Changchun High & New Technology Industries Group Inc stock attractive at the current price?
The data as of Nov 12, 2026: price ¥74.80, calculated fair value ¥61.70 (−18%), Quality Score 45/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000661 calculated?
We run Changchun High & New Technology Industries Group Inc through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥61.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Changchun High & New Technology Industries Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Changchun High & New Technology Industries Group Inc (000661)?
The closing price on Nov 17, 2026 was ¥74.80. Our model-based fair value is ¥61.70, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Changchun High & New Technology Industries Group Inc right now?
The price sits above even our optimistic bull case (¥65.93). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (¥59.20 to ¥65.93), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Changchun High & New Technology Industries Group Inc (000661) come from?
Earnings per share at Changchun High & New Technology Industries Group Inc grew 26.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share +17.6 %, EBIT margin +3.3 %, tax rate +1.2 %, residual (interest, one-offs) +2.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Changchun High & New Technology Industries Group Inc

How large is the market capitalisation of Changchun High & New Technology Industries Group Inc (000661)?
The market capitalisation of Changchun High & New Technology Industries Group Inc is 30.5B CNY (≈ $4.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Changchun High & New Technology Industries Group Inc (000661)?
The price-to-sales ratio of Changchun High & New Technology Industries Group Inc is 2.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Changchun High & New Technology Industries Group Inc (000661)?
Earnings per share at Changchun High & New Technology Industries Group Inc are ¥−0.8700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Changchun High & New Technology Industries Group Inc (000661)?
The dividend yield of Changchun High & New Technology Industries Group Inc is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Changchun High & New Technology Industries Group Inc (000661)?
The net margin of Changchun High & New Technology Industries Group Inc is −3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Changchun High & New Technology Industries Group Inc (000661)?
The return on equity (ROE) of Changchun High & New Technology Industries Group Inc is −2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Changchun High & New Technology Industries Group Inc (000661)?
On an EBIT basis the return on assets of Changchun High & New Technology Industries Group Inc is 14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Changchun High & New Technology Industries Group Inc (000661)?
The operating margin of Changchun High & New Technology Industries Group Inc is 13.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Changchun High & New Technology Industries Group Inc (000661)?
Revenue at Changchun High & New Technology Industries Group Inc is down 18.0% versus a year earlier (3y avg −1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Changchun High & New Technology Industries Group Inc (000661)?
Earnings per share at Changchun High & New Technology Industries Group Inc are down 61.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Changchun High & New Technology Industries Group Inc (000661) generate?
The free cash flow of Changchun High & New Technology Industries Group Inc is −1.4B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Changchun High & New Technology Industries Group Inc (000661) hold?
Changchun High & New Technology Industries Group Inc holds more cash than debt, 4.6B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Changchun High & New Technology Industries Group Inc in the live analysis

One click puts Changchun High & New Technology Industries Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.